Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796350 | 0.89 | RARB (0.39) | CYP4A11CYP4F2RARBTNKS2 | |
| SCHEMBL19804289 | 0.88 | GRM2 (0.36) | CYP4A11CYP4F2GRM2RARBTNKS2 | |
| SCHEMBL19804216 | 0.83 | CA1 (0.36) | CYP4A11CYP4F2GRM2RARBFFAR4 | |
| SCHEMBL19804082 | 0.80 | CTSA (0.36) | RARBFFAR4HDAC1KDM1A | |
| SCHEMBL19804232 | 0.80 | PRKAB2 (0.40) | FFAR4 | |
| SCHEMBL17484412 | 0.78 | RARB (0.35) | CYP4A11CYP4F2GRM2RARBFFAR4 | |
| SCHEMBL19804102 | 0.78 | CYP4F2 (0.41) | CYP4A11CYP4F2GRM2FFAR4HDAC1 | |
| SCHEMBL19796352 | 0.78 | RARB (0.36) | CYP4A11CYP4F2RARB | |
| SCHEMBL19804118 | 0.77 | CA1 (0.36) | CYP4A11CYP4F2TNKS2FFAR4 | |
| SCHEMBL17484398 | 0.77 | RARB (0.46) | CYP4A11RARBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CYP4A11 1991/4885CYP4F2 2577/4885GRM2 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.